Clinical Trials Logo

Clinical Trial Summary

This is a phase III, randomized, comparator-controlled, double-blind, multicenter study to evaluate lot-to-lot consistency of three lots of a PIKA Rabies Vaccine, immunogenicity and safety in healthy adults using a post-exposure prophylaxis schedule. It is also the aim of this study to evaluate non-inferiority and superiority of the PIKA Rabies Vaccine compared to the rabies vaccine comparator ChiroRab.


Clinical Trial Description

This is a phase III, randomized, comparator-controlled, double-blind, multicenter study to evaluate lot-to-lot consistency of three lots of a PIKA Rabies Vaccine, immunogenicity and safety in healthy adults using a post-exposure prophylaxis schedule. It is also the aim of this study to evaluate non-inferiority and superiority of the PIKA Rabies Vaccine compared to the rabies vaccine comparator ChiroRab. A total of 4,500 subjects will be enrolled in the study randomized into 2:1 with 3000 subjects allocated to PIKA rabies vaccine and 1,500 allocated to receive the comparator rabies vaccine ChiroRab . There will be two study Groups: Group 1 (20%) and Group 2 (80%). Within each study group, subjects will be randomly allocated in a 2:2:2:3 ratios to receive 1 of the 3 lots of PIKA rabies vaccine or ChiroRab. The ChiroRab group will receive the classic Essen 5 dose regimen (1-1-1-1-1 schedule on Days 0, 3, 7, 14 and 28), whilst the PIKA rabies vaccine group will receive an accelerated regimen (2-2-1 schedule with a double-dose injection on Days 0 and 3 and a single-dose injection on Day 7). For blinding purposes, normal saline will be injected on Days 14 and 28 for PIKA rabies group and Days 0 and 3 for ChiroRab group. Group 1 will enrol a total of 900 subjects, approximately 20% of the total sample population. Subjects will be randomized at 2:2:2:3 ratio (PIKA lot #1: 200 subjects, PIKA lot #2: 200 subjects, PIKA lot #3: 200 and 300 will be randomized to receive ChiroRab). Blood will be collected pre-vaccination (Day 0) and post-vaccination on Days 7, 14, 28, 90, 180 and 365 to evaluate the primary immunogenicity, safety and secondary immunogenicity endpoints. Subjects will be followed up for the whole study period through clinic visits or phone calls. The first 50 participants randomized in each of the 3 PIKA lots and that for the ChiroRab in Goup 1 (200 in total) will form the safety subset and will have additional blood draw for safety laboratory parameters for CBC platelet, urinalysis, serum chemistry and coagulation on Day 0 (prior to vaccination), Day 7 and Day 28. After completion of enrolment in Group 1, Group 2 will enrol the remaining 3,600 subjects at 2:2:2:3 randomization ratio (PIKA lot #1: 800 subjects, PIKA lot #2: 800 subjects, PIKA lot #3: 800 and 1,200 will be randomized to receive ChiroRab). Blood will be collected pre-vaccination on Day 0, 7 and 365 to evaluate key secondary immunogenicity endpoints of superiority, persistence and durability of immune response as well as co-primary safety objective. Subjects will be followed up for the whole study period through clinic visits or phone calls. After each vaccination, all subjects will be observed in the clinical site for at least 30 minutes for immediate reactions and will be followed up for solicited AEs by diary cards 7 days post each vaccination and unsolicited AEs will be collected through Day 41 post first vaccination. All subjects will be monitored for SAEs, SUSARs, AESIs, and AEs leading to study withdrawal for the whole study period. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05667974
Study type Interventional
Source Yisheng Biopharma (Singapore) Pte. Ltd.
Contact
Status Active, not recruiting
Phase Phase 3
Start date September 22, 2023
Completion date February 21, 2025

See also
  Status Clinical Trial Phase
Completed NCT05509049 - Precision Nudging Drives Wellness Visit Attendance at Scale N/A
Not yet recruiting NCT06335121 - Implementation of PrEP Care Among Women in Family Planning Clinics N/A
Not yet recruiting NCT04082091 - Screening, Early Referral and Lifestyle Tailored E_prescription for Cardiovascular Prevention
Terminated NCT01395238 - Enhancing Father's Ability to Support Their Preschool Child N/A
Completed NCT00589173 - An Interactive Preventive Health Record (IPHR) to Promote Patient-Centered Preventive Care N/A
Completed NCT00535665 - Safety and Immunogenicity of an Inactivated Pandemic Influenza Vaccine Phase 2
Completed NCT00995462 - Prevention of Weight Gain in University Students N/A
Completed NCT00814554 - Effectiveness Evaluation of Three Strategies of Promotion of Healthy Dietary and Physical Activity Behaviours to Prevent Weight Excess Among Teenagers N/A
Completed NCT00966212 - Parent Education for Young Teen Females Phase 2/Phase 3
Completed NCT04526873 - Encouraging Annual Wellness Visits Among ACO Beneficiaries N/A
Recruiting NCT06112249 - SAFE Workplace Intervention for People With IDD N/A
Completed NCT04977700 - Using Physical Tracking to Predict Sunburn N/A
Completed NCT04032145 - Characterization of Health Conditions of Visitors of the Montreal Museum of Fine Arts
Completed NCT04785599 - Lymphedema Prevention After Lymph Node Emptying N/A
Recruiting NCT05050266 - Enhancing Mental and Physical Health of Women Veterans N/A
Recruiting NCT01021488 - Rosuvastatin for Preventing Deep Vein Thrombosis Phase 4
Terminated NCT02247258 - Azathioprine in the Prevention of Ileal Crohn's Disease Postoperative Recurrence. Phase 2
Recruiting NCT05903885 - A Cross-sectional Partnership to Improve Prevention N/A
Completed NCT04162977 - Adapting Personality-Targeted Interventions for Reducing Substance Misuse and Related Outcomes in Youth in Youth Protection Services N/A
Terminated NCT03192514 - Electronic Deprescribing Tool for the Prevention of PIP N/A